The study appears online on September 13 in the Journal of Cell Biology (www.jcb.org).
Beta-catenin is a central component of the Wnt signaling pathway that controls cell proliferation and differentiation. Activation of the Wnt pathway stabilizes beta-catenin, allowing it to move into the cell nucleus and control the expression of many different genes.
Michael Caplan’s group at Yale University uncovered a new way in which cells restrain beta-catenin’s activity. Overexpressing CD82 or CD9, members of the tetraspanin family of transmembrane proteins, suppressed Wnt signaling and reduced beta-catenin protein levels. Surprisingly, this decrease did not involve an established pathway of beta-catenin destruction. “We were sort of stumped,” Caplan admits, “until we saw a talk that mentioned that tetraspanins like CD82 are associated with exosomes.”
Exosomes are small vesicles that form inside endosomes by the inward budding of endosomal membranes. The vesicles are then secreted when the endosome fuses with the plasma membrane. The team found that CD9 and CD82 boosted the release of exosomes containing beta-catenin, thereby reducing cellular levels of the protein and inhibiting the Wnt pathway. Cells lacking CD9, on the other hand, produced fewer exosomes and showed higher Wnt signaling activity.
The exosomal release of beta-catenin may be compromised in certain cancers, where Wnt signaling is often hyperactive. CD82 and CD9 are both suppressors of metastasis whose expression is lost in several types of late stage tumor. Caplan and colleagues blocked Wnt signaling in a metastatic cell line after restoring CD82 expression. “CD82 may act as a metastasis suppressor by targeting beta-catenin for exosomal release and thereby reducing its availability as a Wnt signaling mediator,” Caplan proposes.
About The Journal of Cell Biology
Founded in 1955, The Journal of Cell Biology (JCB) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JCB content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jcb.org.
Chairoungdua, A., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201002049.